{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:10Z","timestamp":1762005370512,"version":"3.40.5"},"reference-count":39,"publisher":"Microbiology Society","issue":"4","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,22]]},"abstract":"\n Introduction.<\/jats:bold> Ceftolozane\/tazobactam was approved by the Drug Office, Department of Health, Government of the Hong Kong Special Administrative Region in 2017.<\/jats:p>\n \n Hypothesis\/Gap Statement.<\/jats:bold> Currently the in vitro<\/jats:italic> activity of ceftolozane\/tazobactam against Gram-negative pathogens isolated from patients in Hong Kong is undocumented. It would be prudent to document the activity of ceftolozane\/tazobactam against \n \n Pseudomonas aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> and Enterobacterales isolated from hospitalized patients in Hong Kong.<\/jats:p>\n \n Aim.<\/jats:bold> To describe the in vitro<\/jats:italic> susceptibility of recent clinical isolates of \n \n P. aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> and the two most common Enterobacterales species (\n \n Klebsiella pneumoniae<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>, \n \n Escherichia coli<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>) cultured from respiratory tract, intra-abdominal, urinary tract and bloodstream infection samples to ceftolozane\/tazobactam and other commonly used antimicrobial agents.<\/jats:p>\n \n Methodology.<\/jats:bold> CLSI-defined broth microdilution MICs were determined and interpreted for Gram-negative isolates collected in Hong Kong from 2017 to 2019 by the SMART surveillance programme.<\/jats:p>\n \n Results.<\/jats:bold> For \n \n P. aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>, 96.7\u200a% of isolates (n<\/jats:italic>=210) were susceptible to ceftolozane\/tazobactam, while susceptibility rates were \u226514\u200a% lower to meropenem (82.9\u200a% susceptible), cefepime (82.4\u200a%), ceftazidime (81.4\u200a%), piperacillin\/tazobactam (76.7\u200a%) and levofloxacin (79.5\u200a%). Ceftolozane\/tazobactam inhibited 85.7\u200a% of piperacillin\/tazobactam-nonsusceptible isolates, 80.6\u201382.1\u200a% of cefepime-, ceftazidime- or meropenem-nonsusceptible isolates, and 75.9\u200a% of multidrug-resistant (MDR) isolates of \n \n P. aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>. For \n \n K. pneumoniae<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>, 96.1\u200a% of isolates (n<\/jats:italic>=308) were susceptible to ceftolozane\/tazobactam compared with meropenem (99.0\u200a% susceptible), piperacillin\/tazobactam (93.8\u200a%), cefepime (85.7\u200a%) and ceftazidime (85.4\u200a%). The majority (88.3\u200a%) of ESBL (extended-spectrum \u03b2-lactamase) non-CRE (carbapenem-resistant Enterobacterales) phenotype isolates of \n \n K. pneumoniae<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> were susceptible to ceftolozane\/tazobactam, comparable to piperacillin\/tazobactam (85.0\u200a%) but lower than meropenem (100\u200a%). For \n \n E. coli<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>, 98.5\u200a% of isolates (n<\/jats:italic>=609) were susceptible to ceftolozane\/tazobactam compared to meropenem (99.3\u200a% susceptible), piperacillin\/tazobactam (96.7\u200a%), ceftazidime (82.3\u200a%) and cefepime (76.5\u200a%). The majority (96.7\u200a%) of ESBL non-CRE phenotype isolates of \n \n E. coli<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> were susceptible to ceftolozane\/tazobactam, similar to both meropenem (100\u200a%) and piperacillin\/tazobactam (94.5\u200a%).<\/jats:p>\n \n Conclusions.<\/jats:bold> Overall, >96\u200a% of clinical isolates of \n \n P. aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>, \n \n K. pneumoniae<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> and \n \n E. coli<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic> collected in Hong Kong in 2017\u20132019 were susceptible to ceftolozane\/tazobactam, while the activity of several commonly prescribed \u03b2-lactams was reduced, especially for \n \n P. aeruginosa<\/jats:ext-link>\n <\/jats:named-content>\n <\/jats:italic>. Continued surveillance of ceftolozane\/tazobactam and other agents is warranted.<\/jats:p>","DOI":"10.1099\/jmm.0.001487","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:17:36Z","timestamp":1650640656000},"source":"Crossref","is-referenced-by-count":6,"title":["Activity of ceftolozane\/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017\u20132019"],"prefix":"10.1099","volume":"71","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, R3E 0J9, Canada"},{"name":"IHMA, Schaumburg, IL, 60173, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle H.","family":"Lob","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, IL, 60173, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Khan","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs, MSD (Asia) Ltd., Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"MSD, Taipei, Taiwan, ROC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C. Y.","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Hong Kong, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-9200","authenticated-orcid":false,"given":"Wing Hong","family":"Seto","sequence":"additional","affiliation":[{"name":"School of Public Health, WHO Collaborating Centre, University of Hong Kong, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-6537","authenticated-orcid":false,"given":"Margaret","family":"Ip","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Leung","sequence":"additional","affiliation":[{"name":"Clinical Laboratories and Pathology, Hong Kong Adventist Hospital, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-7419","authenticated-orcid":false,"given":"Queenie W.-L.","family":"Wong","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs, MSD (Asia) Ltd., Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene W. Y.","family":"Chau","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs, MSD (Asia) Ltd., Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-5455","authenticated-orcid":false,"given":"Katherine","family":"Young","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-8475","authenticated-orcid":false,"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ 07033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, IL, 60173, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.003"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw102"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.07.012"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2015.05.005"},{"volume-title":"Reducing Bacterial Resistance with IMPACT","year":"2017","author":"Ho","key":"R7"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky425"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105883"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105891"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.09.016"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02431-18"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx136"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-20"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00875"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S279020"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq248"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02125-17"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.114925"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.011"},{"volume-title":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing","key":"R25"},{"volume-title":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically \u2013 Eleventh Edition","key":"R26"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03681-14"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa291"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx424"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01822-19"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01183-17"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-15"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-15"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-417"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz816"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab295"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.030"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.008"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001487?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:17:45Z","timestamp":1650640665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,22]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.001487","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"type":"print","value":"0022-2615"},{"type":"electronic","value":"1473-5644"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}